Search

everythinglearnresearchcommunity

for

Search:↓

Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

Low vitamin D levels might indicate more severe hair loss in alopecia areata patients.

JAK inhibitors offer new hope for treating severe alopecia areata.

People with severe alopecia areata often have lower vitamin D levels and may have other autoimmune or allergic conditions.

People with severe Alopecia Areata have higher levels of TGF-β1, which may play a role in the condition.

Topical cyclosporin-A is recommended for severe alopecia areata.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.

Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

More effective treatments are needed for severe alopecia areata.

Higher concentrations of dithranol can help regrow hair in severe alopecia areata.

Higher inflammation markers are linked to more severe alopecia areata.

Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.

The conclusion is that in the Indian subcontinent, socioeconomic status, stress, and family structure affect the severity of alopecia areata, and its psychological impact is generally mild or moderate.

Higher IgE levels may play a role in alopecia areata, especially in males, children, and severe cases.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Ayurvedic herbs may reduce side effects and improve effectiveness of cancer treatments.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.